AI momentum offsets near-term margin pressure; guidance flat

Revenue ₹24752.7 Cr, YoY +9.1% reported (+0.6% constant currency), QoQ +1.1% reported

Delivered OPM 19.6%, well above guidance band; discrepancy on communicated 16.5% figure vs actual

Pipeline cited as 'extremely strong' for Q3-Q4 but no numeric verification in results; TCV figure not auditable from P&L

Net profit ₹3199.7 Cr, -1.9% YoY, -4.7% QoQ; discrepancy on YoY metric (management cited INR basis vs reported)

Cash flow metric aligns with strong balance sheet, gross cash ₹4.6B; cash generation supported

BFSI growth stated in call; sector-level data not in main result but growth narrative internally consistent

Healthcare declined substantially YoY; management acknowledged policy headwinds; Q3 recovery is forward claim, unverified

Q2 outlook was -1.5% to +0.5% sequential; Q3 guidance identical, indicating management confidence in macro recovery absent

Exceeded in Q2 (19.6%), but AI investments and cost pressures expected to pull margins back to band; no margin upgrade implied

AI-Native Unit launched April 2026 with 2000+ engineers, FDEs; new SLMs for wealth, insurance, healthcare, aviation; moving beyond inherited consulting to platform plays

Q2 TCV $2.6B and 9 large deals strong, but some Q2 deals deferred to Q3 due to paperwork; pipeline robust but conversion risk remains

US healthcare policy changes cited as ongoing pressure; membership growth slowing; policy-driven cost controls expected to persist

Some deals in Q2 could not be signed on time due to paperwork issues; two deals we expected in Q2 will sign in Q3. Pipeline for Q3/Q4 is extremely strong and very optimistic on closure.

Four opportunities in GCCs: greenfield (client sets up new centers), brownfield (enhance existing), monetization (convert internal centers to client services), and partnership. Not a major threat; we see upside in all four models.

AI adoption happening across all layers: consulting, services, and infrastructure. We position across the full value chain via Build AI (WEGA), Run AI (WINGS), Reimagine AI (AI-Native Unit). Not seeing excessive leverage; clients value integrated solutions.

BFSI grew 1% sequentially, 1.3% YoY. Some good wins announced; Capco (our consulting arm) doing well across continents; momentum building. Banking specifically seeing data modernization and AI-ready data foundation work ramping.

US healthcare impacted by policy changes; cost pressures from membership growth slowdown and payer consolidation. We expect benefit from seasonality in Q3 and building demand for first-time outsourcers.

Year-on-year attrition is high; we're optimizing campus hiring and driving productivity from AI projects. Will continue going forward. Not unusual seasonal furlough impacts.

Mindprint (from Olam deal) and Harman DTS (design, manufacturing capabilities) added incremental revenue and expanded addressable markets. Inorganic contribution immaterial in Q2; will scale in coming quarters. Core endgame: organic growth with margin expansion.

Furloughs are seasonal, expected broadly in line with prior year. Q4 outlook depends on deal closures and pipeline execution. Confident in strong pipeline for Q3, Q4, and beyond; will share more detail in January.

All three are active. Build AI (WEGA for product/SDLC) is core. Run AI (WINGS for productivity/velocity) helps clients improve efficiency and experience. Reimagine AI (AI-Native platforms for vertical segments like wealth, insurance, aviation, telecom) is emerging and highly investable.

No change in demand environment. Clients focused on efficiency and productivity while accelerating AI adoption. Some sector-by-sector variation (BFSI strong, healthcare challenged), but overall demand for higher-value transformation is accelerating.

Reflects seasonal furloughs in Dec quarter, macro uncertainty, and some deal conversion timing. Range acknowledges upside from pipeline but caution on near-term execution.

Qualitative guidance; no specific FY27 revenue target provided. Management emphasizes organic growth priority over inorganic M&A.

Q2 delivered 19.6% OPM, exceeding band. Management expects margins to move toward target band due to investments in AI-Native Unit and platform development. Messaging suggests near-term margin compression from AI spending.

Investments in R&D and platform development are embedded in operating margin guidance. No formal CapEx budget disclosed.

Client cost optimization and vendor consolidation reduce discretionary consulting and transformation spending. Q3 guidance -1.5% to +0.5% sequential, flat demand environment acknowledged, limiting near-term growth.

Healthcare segment headwind due to Medicaid/Medicare reform, membership growth slowdown, payer consolidation. Enrollment impact substantial (18% decline from Q1). Recovery timing uncertain.

Sequential PAT fell 4.7% despite +1.1% revenue growth, driven by lower other income (68% decline QoQ after June buyback completion) and margin pressure from AI investments. Signals near-term profitability risk.

9.1% YoY revenue growth includes ~8.5% FX tailwind; underlying +0.6% constant currency growth is modest, masking macro weakness.

Some Q2 deals deferred to Q3 due to paperwork/approvals; pipeline cited as 'extremely strong' but unquantified. Ability to close bookings on schedule is critical for Q3-Q4 growth.

6,500+ head count reduction in Q2; attrition described as high YoY. Optimizing campus hiring may crimp bench and delay staffing for deal ramps.